192 related articles for article (PubMed ID: 24142827)
21. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Pettengell R; Bias P; Mueller U; Lang N
Support Care Cancer; 2016 Jun; 24(6):2677-84. PubMed ID: 26780505
[TBL] [Abstract][Full Text] [Related]
22. Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study.
Tamura K; Hashimoto K; Nishikawa K
J Infect Chemother; 2018 May; 24(5):363-369. PubMed ID: 29398477
[TBL] [Abstract][Full Text] [Related]
23. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Crawford J
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
[TBL] [Abstract][Full Text] [Related]
25. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
26. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
[TBL] [Abstract][Full Text] [Related]
27. Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy.
Siena S; Secondino S; Giannetta L; Carminati O; Pedrazzoli P
Crit Rev Oncol Hematol; 2003 Oct; 48(Suppl):S39-47. PubMed ID: 14563520
[TBL] [Abstract][Full Text] [Related]
28. Pegfilgrastim use during chemotherapy: current and future applications.
Wolf T; Densmore JJ
Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
[TBL] [Abstract][Full Text] [Related]
30. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
[TBL] [Abstract][Full Text] [Related]
31. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Crawford J; Becker PS; Armitage JO; Blayney DW; Chavez J; Curtin P; Dinner S; Fynan T; Gojo I; Griffiths EA; Hough S; Kloth DD; Kuter DJ; Lyman GH; Mably M; Mukherjee S; Patel S; Perez LE; Poust A; Rampal R; Roy V; Rugo HS; Saad AA; Schwartzberg LS; Shayani S; Talbott M; Vadhan-Raj S; Vasu S; Wadleigh M; Westervelt P; Burns JL; Pluchino L
J Natl Compr Canc Netw; 2017 Dec; 15(12):1520-1541. PubMed ID: 29223990
[TBL] [Abstract][Full Text] [Related]
32. Colony-stimulating factors in the management of neutropenia and its complications.
Heuser M; Ganser A
Ann Hematol; 2005 Oct; 84(11):697-708. PubMed ID: 16047204
[TBL] [Abstract][Full Text] [Related]
33. Pegfilgrastim.
Curran MP; Goa KL
Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
[TBL] [Abstract][Full Text] [Related]
34. Advances in the use of colony-stimulating factors for chemotherapy-induced neutropenia.
Dale DC
J Support Oncol; 2005; 3(2 Suppl 1):39-41. PubMed ID: 15794500
[No Abstract] [Full Text] [Related]
35. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
36. Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.
Ng R; Green MD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):585-90. PubMed ID: 16111460
[TBL] [Abstract][Full Text] [Related]
37. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
38. Cost considerations in therapy with myeloid growth factors.
Glaspy JA; Jakway J
Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
[TBL] [Abstract][Full Text] [Related]
39. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
Waladkhani AR
Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
[TBL] [Abstract][Full Text] [Related]
40. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]